Amantadine for ADHD Treatment

Established ADHD Medications

The American Academy of Pediatrics recommends stimulants (methylphenidate and amphetamines) as the first-line pharmacological treatment for ADHD due to their large effect sizes, rapid onset of action, and extensive evidence base 1, 2
Stimulants have demonstrated superior efficacy compared to non-stimulant medications for reducing core ADHD symptoms, with a strong evidence base supporting their use 1, 3
Atomoxetine (norepinephrine reuptake inhibitor) is the primary second-line treatment when stimulants are ineffective or poorly tolerated, according to the American Academy of Child and Adolescent Psychiatry 1, 2
Alpha-2 adrenergic agonists (clonidine, guanfacine) are also established non-stimulant options with evidence supporting their efficacy, as recommended by the American Academy of Child and Adolescent Psychiatry 1, 4

For children (6-11 years) and adolescents (12-18 years), the American Academy of Pediatrics recommends beginning with FDA-approved stimulant medications (methylphenidate or amphetamine formulations) 3
If stimulants are ineffective or poorly tolerated, the American Academy of Pediatrics recommends switching to atomoxetine 1, 2
The American Academy of Child and Adolescent Psychiatry recommends considering alpha-2 agonists (guanfacine, clonidine) as alternative non-stimulants 1, 4

The American Academy of Pediatrics, European, and Asian countries' guidelines do not list amantadine as a recommended treatment for ADHD, due to its limited evidence base 1, 2, 3, 5, 6
When selecting ADHD medications, clinicians should consider the severity of symptoms, presence of comorbidities, duration of symptom control needed, patient/family preferences, and side effect profiles, as recommended by the American Academy of Pediatrics and the American Academy of Child and Adolescent Psychiatry 1, 2